Sutro Biopharma, Inc., a clinical-stage drug development and manufacturing company focused on the application of precise protein engineering to create next-gen oncology therapeutics, has achieved a clinical supply milestone under its collaboration and license agreement with Merck KGaA, and is entitled to receive a milestone payment. The candidate, M1231, was discovered using Sutro’s XpressCF and XpressCF+ drug discovery and manufacturing technologies and includes a linker-warhead disco...